Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
1-15 of 2349 results
PTC Therapeutics agrees to buy Marathon's DMD drug for $140m
PTC Therapeutics has agreed to acquire all rights to Emflaza (deflazacort) from Marathon Pharmaceuticals.
Contract Research & Services > Contract Services > News
Advaxis licenses antigen delivery technology to Sellas for cancer immunotherapy development
Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
Contract Research & Services > Contract Services > News
Horizon Discovery signs master service deal with top three global pharmaceutical firm
Horizon Discovery Group has signed a Master Services Agreement (MSA) with a top three global pharmaceutical company, extending support for their drug discovery and development efforts to its full suite of services.
Contract Research & Services > Contract Services > News
Neurotrope signs licensing deal for accelerated synthesis of Alzheimer’s drug Bryostatin-1
Neurotrope has signed a licensing agreement with Stanford University for an accelerated synthesis of Alzheimer's drug bryostatin-1.
Contract Research & Services > Contract Services > News
Abzena signs licensing deal for ThioBridge antibody drug conjugate linker technology
Abzena has entered into a licensing agreement with with a San Diego-based biopharmaceutical firm for its novel site-specific ThioBridge antibody drug conjugate (ADC) linker technology.
Contract Research & Services > Contract Services > News
Cumberland Pharmaceuticals, Clinigen sign US commercialization deal for Totect
Cumberland Pharmaceuticals and Clinigen Group have signed an exclusive agreement to commercialize the oncology support drug, Totect (dexrazoxane hydrochloride) in the US.
Contract Research & Services > Contract Services > News
Novartis signs potential $1bn deal with Ionis and Akcea on cardiovascular treatments
By PBR Staff Writer
Novartis has agreed to pay more than $1bn to Ionis Pharmaceuticals and its subsidiary Akcea Therapeutics for the rights to two cardiovascular drugs.
Contract Research & Services > Contract Services > News
Dermavant licenses cerdulatinib from Portola for topical applications
Dermavant Sciences has signed an exclusive worldwide licensing agreement with Portola Pharmaceuticals for the development and commercialization of cerdulatinib in topical applications beyond oncology.
Contract Research & Services > Contract Services > News
Bristol-Myers secures rights to PsiOxus’ armed oncolytic virus
By PBR Staff Writer
Bristol-Myers Squibb has signed an agreement worth up to $936m plus royalties to secure global rights to an armed oncolytic virus being developed by PsiOxus Therapeutics to treat solid tumors.
Contract Research & Services > Contract Services > News
VistaGen sublicenses rights to stem cell-related technologies to BlueRock Therapeutics
VistaGen Therapeutics has signed an exclusive sublicense agreement with BlueRock Therapeutics for rights to certain technologies relating to the production of cardiac stem cells for the treatment of heart disease.
Contract Research & Services > Contract Services > News
Grünenthal to buy rights to PNP drug from Astellas Pharma Europe
Grünenthal has agreed to acquire commercialization rights of Qutenza in Europe from Astellas Pharma Europe.
Contract Research & Services > Contract Services > News
AstraZeneca, Eli Lilly partner for another Alzheimer's drug
By PBR Staff Writer
Pharmaceutical giants AstraZeneca and Eli Lilly are expanding their collaboration to develop an experimental Alzheimer's drug.
Contract Research & Services > Contract Services > News
Sermonix signs licensing deal to further explore lasofoxifene for breast cancer treatment
Sermonix Pharmaceuticals has signed a licensing agreement to gain exclusive rights to Duke University intellectual property related to the use of lasofoxifene, its lead investigational drug, in the treatment of endocrine-resistant breast cancer.
Contract Research & Services > Contract Services > News
Purdue Pharma, AnaBios partner to advance research for non-opioid, non-NSAID compounds
Purdue Pharma and AnaBios have partnered to advance the research of non-opioid, non-NSAID compounds for the treatment of chronic pain.
Contract Research & Services > Contract Services > News
Aegerion Pharmaceuticals signs licensing deal with Amryt Pharma for Lojuxta
Novelion Therapeutics' subsidiary, Aegerion Pharmaceuticals has entered into a licensing agreement with Amryt Pharma (“Amryt”) for the exclusive rights to LOJUXTA (lomitapide) hard capsules in certain European and Middle Eastern territories.
Contract Research & Services > Contract Services > News
1-15 of 2349 results